Canada Drugs Direct

Visiting from Canada?

Want to save up to 80% on your medications? Signup below to be notified if we open a Canadian Online Pharmacy.

I agree to receive email updates from Canada Drugs Direct

Looking for Call us toll free 1-800-500-2897

Adtralza (Tralokinumab)

Prescription medicineOnly Available By Prescription

What if I find a lower price with another pharmacy?

We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!

Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.

To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.

Terms & Conditions of Program

  • Guaranteed lowest price is only valid at the time of sale.
  • We will only match the current advertised price.
  • Products must be identical and in stock at the time of placing an order with a licensed mail order pharmacy. They must be an online Canadian pharmacy with an address in Canada.
  • Products must be authentic in brand and size (same manufacturer, same country of manufacture, same pack size, same strength and same quantity).
  • Products must be new. We cannot match the price of any used, short expiry or expired product.
  • Price match can only be issued over the phone with our customer service team. Please note at this time we cannot offer price matching for the products Ozempic or Saxenda.
What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.


Adtralza, known by its generic name Tralokinumab, is a monoclonal antibody used to treat adults and children over 12 with moderate to severe atopic dermatitis (eczema). It specifically targets a cytokine, interleukin-13 (IL-13), involved in the inflammation caused by eczema. Classified as an IgG4 monoclonal antibody, Tralokinumab may help manage symptoms when topical prescription treatments are not effective or appropriate. This biologic therapy can be used alone or in combination with topical corticosteroids.


Adtralza is administered as an injection under the skin (subcutaneously). For adults and children aged 12 years and older with moderate-to-severe atopic dermatitis, it is typically given as an initial dose of 600 mg, followed by 300 mg every other week. Follow a healthcare provider's instructions on how and where to inject, as this medication can be used with or without topical corticosteroids. Before taking the injection, check the solution for particles or discoloration and use the proper technique to avoid infection at the injection site.


The active ingredient in an Adtralza injection is Tralokinumab.


Do not use this medication if you have a known hypersensitivity to Tralokinumab or any of the ingredients in Adtralza. Those who have had severe allergic reactions to biologics or similar medications may also need to avoid this drug.


  • Before using Adtralza, consult your doctor or healthcare provider about the following:
    • All medications you’re taking.
    • Any medical conditions you have.
    • Whether you’re pregnant or breastfeeding.
  • When you receive Adtralza, the name and batch number of the product should be clearly recorded. This helps in improving the traceability of the product.
  • If you experience any immediate or delayed hypersensitivity reaction after taking Adtralza, such as rash, itching, or difficulty breathing, the treatment should be stopped, and you should seek appropriate medical care.
  • Should you develop conjunctivitis that doesn’t get better with standard treatment while using Adtralza, an eye exam may be recommended.
  • If you have a pre-existing helminth infection, it's recommended to get treated for it before starting Adtralza. Also, if you acquire a helminth infection during treatment and do not respond to standard treatment, you may need to stop Adtralza until the infection resolves.
  • Avoid live and live attenuated vaccines while on Adtralza, as their safety and effectiveness when given with this medication have not been established. Make sure your vaccinations are up to date according to current immunization guidelines before starting Adtralza.

Side Effects

Adtralza may cause side effects that patients should be aware of. Common side effects may include body aches or pain, burning or itching eyes, chills, cough, and ear congestion. Patients might also experience a fever, headache, or a stuffy or runny nose. These side effects are usually manageable and resolve on their own.

In some instances, Adtralza may cause serious side effects, such as severe redness, pain, and swelling of the eye, eyelid, or inner lining of the eyelid. Severe allergic reactions are rare but possible and may cause symptoms such as difficulty breathing or swelling of the face and throat. Seek emergency medical care if you experience any severe reactions.


  1. Adtralza (Tralokinumab) Summary of Product Characteristics. Ballerup, Denmark: LEO Pharma; 2021.
  2. Adtralza (Tralokinumab) Medicine Overview. Amsterdam, The Netherlands: European Medicines Agency; 2022.

IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

product reviews icon Product Reviews